SCHEMBL3097336

SCHEMBL3097336

O=C(NS(=O)(=O)c1ccc2ccccc2c1)C(Cc1ccccc1)C(=O)N1CCN(S(=O)(=O)c2ccc3ccccc3c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 7/20 0.60
PLG P00747 3/20 0.58
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RAB9A P51151 1/20 0.54
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CAPN1 P07384 1/20 0.51
TGM2 P21980 1/20 0.50
PABPC1 P11940 1/20 0.50
APOBEC3A P31941 1/20 0.50
EIF4H Q15056 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
ATM Q13315 1/20 0.50
F2 P00734 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3084979 0.83 PLG (0.46) PKMPLGF2
SCHEMBL3090754 0.82 F2 (0.49) PKMPLGF2
SCHEMBL3090840 0.81 LARS1 (0.58) ALDH1A1LMNAL3MBTL1F2
SCHEMBL3101110 0.80 F10 (0.50) PLGMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL3089259 0.80 NPC1 (0.46) PLGRAB9AALDH1A1SMN1; SMN2F2
SCHEMBL3092893 0.80 MMP8 (0.53) PLGMEN1KMT2AALDH1A1LMNA
SCHEMBL3096727 0.79 F10 (0.51) PLGF2
SCHEMBL3095973 0.79 F2 (0.48) PKMF2
SCHEMBL8161058 0.78 PLG (0.71) PKMPLGF2
SCHEMBL3096410 0.78 MMP8 (0.51) PLGMEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 PKM 1468/4885PLG 2448/4885MEN1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.